Our findings confirm the promise of USP11-targeting therapy against AD and further underscore the potential of IsoLiPro as a novel, orally active small-molecule USP11 inhibitor, offering a promising therapeutic approach for AD. Here, USP11 is linked to Alzheimer disease.